Back to search results

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Abroad (travel likely)RecruitingPHASE3

Conditions

Higher-risk Myelodysplastic Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Guillermo Garcia-Manero, M.D.) · ggarciam@mdanderson.org · 713-745-3428
    Contact: Principal Investigator (Guillermo Garcia-Manero, M.D.)

  • Peking University People's Hospital, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Xiaojun Huang, M.D.,Ph.D.) · xjhrm@medmail.com.cn · 010-88325229
    Contact: Principal Investigator (Xiaojun Huang, M.D.,Ph.D.)
Study leads

  • Xiaojun Huang, M.D., Ph.D.

    Study Chair

    Peking University People's Hospital

  • Guillermo Garcia-Manero, M.D.

    Study Chair

    M.D. Anderson Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)